Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!

Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!

Today’s pre-market activity highlights significant developments from a range of innovative companies, driving early market attention. Stocks making notable moves include Peraso Inc., Tevogen Bio, ZenaTech, CCSC Technology, and Cardiol Therapeutics, each drawing investor interest with critical announcements and high trading volumes.

Peraso Inc. (NASDAQ: PRSO) announced securing a $1.4 million follow-on order from a South African wireless Internet service provider, further showcasing the demand for its mmWave technology in high-density urban markets. This order follows a previous production shipment earlier in the year and solidifies Peraso’s standing in the wireless connectivity sector.

Tevogen Bio (Nasdaq: TVGN) reported that its artificial intelligence division, Tevogen AI, has joined Microsoft's Startups program, accelerating its drug development initiatives by leveraging Microsoft’s AI capabilities. This partnership marks a key milestone in the company’s mission to expedite drug discovery and reduce costs.

ZenaTech, Inc. (Nasdaq: ZENA) revealed that its subsidiary, ZenaDrone, has acquired a U.S. Design Patent for its second-generation ZenaDrone 1000, significantly enhancing flight times and increasing payload capacity to 80 lbs. This development marks a crucial step forward in ZenaTech’s AI-driven drone technology.

CCSC Technology (NASDAQ: CCTG) saw speculative premarket trading today despite the absence of news, with the company’s diverse portfolio of OEM and ODM interconnect products for industries like automotive, robotics, and telecommunications making it a frequent target for market speculation.

Cardiol Therapeutics (NASDAQ: CRDL) announced plans to advance its CardiolRx™ therapy into the MAVERIC-2 late-stage clinical trial, which will evaluate its effectiveness in treating recurrent pericarditis. The trial is expected to begin in Q4, running alongside the company's upcoming Phase III study across the U.S. and Europe.

As these companies drive innovation in technology, biotechnology, and wireless communication, premarket trading is buzzing with activity. Investors will be closely watching the unfolding developments to gauge their potential market impacts throughout the day.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.